Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

vTv Therapeutics (VTVT) Accounts Payables (2016 - 2025)

vTv Therapeutics (VTVT) has disclosed Accounts Payables for 12 consecutive years, with $6.6 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 30.44% to $6.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.6 million through Dec 2025, up 30.44% year-over-year, with the annual reading at $6.6 million for FY2025, 30.44% up from the prior year.
  • Accounts Payables hit $6.6 million in Q4 2025 for vTv Therapeutics, down from $9.8 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $12.5 million in Q1 2022 to a low of $4.2 million in Q1 2025.
  • Historically, Accounts Payables has averaged $7.4 million across 5 years, with a median of $7.1 million in 2022.
  • Biggest five-year swings in Accounts Payables: surged 151.24% in 2022 and later crashed 52.0% in 2025.
  • Year by year, Accounts Payables stood at $8.0 million in 2021, then decreased by 8.85% to $7.3 million in 2022, then skyrocketed by 40.05% to $10.2 million in 2023, then plummeted by 50.92% to $5.0 million in 2024, then soared by 30.44% to $6.6 million in 2025.
  • Business Quant data shows Accounts Payables for VTVT at $6.6 million in Q4 2025, $9.8 million in Q3 2025, and $5.2 million in Q2 2025.